CAH

Cardinal Health, Inc. (CAH) - Q3 Fiscal 2025 Form 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended March 31, 2025 (Q3 Fiscal 2025). Cardinal Health is a global healthcare services and products company operating through two primary reportable segments: Pharmaceutical and Specialty Solutions (Pharma) and Global Medical Products and Distribution (GMPD). The "Other" category includes Nuclear and Precision Health Solutions, at-Home Solutions, and OptiFreight Logistics. The company's fiscal year ends on June 30.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue: Q3 revenue was flat year-over-year, while YTD revenue decreased 3%. This decline is primarily attributed to the expiration of the Pharma segment's OptumRx contracts in June 2024, which previously generated 17% of consolidated revenue. This was partially offset by growth in branded and specialty pharmaceutical sales.
• Profitability: GAAP operating earnings surged 98% in Q3 and significantly increased YTD. This improvement is largely due to the absence of the $90 million (Q3) and $675 million (YTD) goodwill impairment charges recorded in the GMPD segment during the prior year. Additionally, the company recognized net litigation recoveries of $106 million in Q3 and $176 million YTD, compared to charges in the prior year.
• Acquisitions: The company completed significant acquisitions, including a 73% interest in GI Alliance (GIA) for $2.8 billion and Integrated Oncology Network (ION) for $1.1 billion. These transactions increased amortization and acquisition-related costs but contributed to segment profit growth.
• Interest Expense: Net interest expense increased significantly (Q3: $74 million vs. $28 million; YTD: $141 million vs. $42 million) due to new debt financing issued to fund acquisitions.

Guidance, Outlook, and Risks

• Outlook: Management expects some adverse impacts from the OptumRx contract expiration to continue through the remainder of Fiscal 2025, though these are being offset by new customer onboarding and cost savings. The company anticipates positive revenue and profit impacts from recent acquisitions (GIA, ION, ADSG) in future periods.
• Tariffs: Recent U.S. tariffs on China, Mexico, Canada, and other countries pose a risk of increased sourcing costs and potential supply disruptions. The company is taking action to mitigate these impacts but notes uncertainty regarding final tariff rates and the ability to pass costs to customers.
• Litigation: The company has accrued $4.9 billion related to national opioid litigation settlements, with payments expected to continue through 2038. YTD payments totaled $797 million. The company continues to vigorously defend against remaining private plaintiff lawsuits.
• Capital Allocation: The company deployed $1.1 billion for ION, $2.8 billion for GIA, and $1.1 billion for ADSG. It also issued $2.9 billion in new long-term debt. Share repurchases totaled $765 million YTD, with $2.7 billion remaining under the current authorization.

Investor Verification Checklist

• OptumRx Replacement: Verify the rate of new customer onboarding and revenue growth from branded/specialty pharmaceuticals to ensure they fully offset the loss of OptumRx volume.
• Acquisition Integration: Monitor the integration progress and profitability contribution of GIA, ION, and ADSG, specifically regarding the realization of expected synergies.
• Debt Servicing: Assess the impact of increased interest expense on future cash flows given the $2.9 billion in new debt issued in late 2024.
• Opioid Litigation Exposure: Review the $4.9 billion accrual and the timeline of future payments to ensure liquidity remains adequate for settlement obligations through 2038.
• Tariff Impact: Evaluate the company's ability to pass on increased costs from tariffs to customers without losing market share to competitors.